ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life)

• Status: Completed
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Comparison of clinical efficacy and safety of levocetirizine in PER continuous versus on demand, measured by evolution of individual symptom scores during 6 months.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UCB Pharma; UCB S.A. - Pharma Sector
• Treatments: Cetirizine; Levocetirizine

Criteria

Inclusion Criteria:

• Clinical history of Persistent allergic Rhinitis (PER) requiring treatment known at least since 2 years.

• Positive skin prick test (wheal > 3 mm larger than the diluent control) or Radio Allergo Sorbent Assay (RAST) (>= 3.5 IU/ml) to House Dust Mite (HDM) and Parietaria (less than 1 year).

• Minimum mean Total 4 Symptom Score (T4SS) of 6 over baseline period.

Exclusion Criteria:

• Subjects currently treated by specific parietaria pollen immunotherapy

• Subjects suffering from non-allergic asthma

• Chronic use of inhaled steroids and/or long acting β2 agonists; and/or corticosteroids dependent asthma (severe asthma)

• Atopic dermatitis or urticaria requiring antihistamine treatment or the administration of oral or topical corticosteroids